Trial Helps Unravel Migraine-Depression Knot

Neurology
>
Migraines

—
Fremanezumab reduced depression symptoms and migraine days in people with both disorders

by
Judy George, Deputy Managing Editor, MedPage Today
May 6, 2025 • 3 min read

Fremanezumab reduced migraine attacks and depression symptoms in migraine patients with major depressive disorder.Migraine and major depression are frequently comorbid.Fremanezumab selectively targets CGRP and is approved for migraine prevention.

Fremanezumab (Ajovy) reduced depression symptoms and monthly migraine attacks in people with episodic or chronic migraine and major depressive disorder, the phase IV UNITE trial showed.

The mean change from baseline in monthly migraine days during a 12-week double-blind period was -5.1 days (95% CI -6.09 to -4.13) with fremanezumab and -2.9 days (95% CI -3.89 to -1.96) with placebo (P